OA11069A - Intranasal formulations for treating sexual disorders - Google Patents

Intranasal formulations for treating sexual disorders Download PDF

Info

Publication number
OA11069A
OA11069A OA9900137A OA9900137A OA11069A OA 11069 A OA11069 A OA 11069A OA 9900137 A OA9900137 A OA 9900137A OA 9900137 A OA9900137 A OA 9900137A OA 11069 A OA11069 A OA 11069A
Authority
OA
OAPI
Prior art keywords
intranasal
sildenafil
formulation
mesylate
solution
Prior art date
Application number
OA9900137A
Other languages
English (en)
Inventor
Ann Billotte
Peter James Dunn
Brian Thomas Henry
Peter Vallance Marshall
Joanna Jayne Woods
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9813452.1A external-priority patent/GB9813452D0/en
Priority claimed from GBGB9820837.4A external-priority patent/GB9820837D0/en
Priority claimed from GBGB9903177.5A external-priority patent/GB9903177D0/en
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of OA11069A publication Critical patent/OA11069A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA9900137A 1998-06-22 1999-06-18 Intranasal formulations for treating sexual disorders OA11069A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9813452.1A GB9813452D0 (en) 1998-06-22 1998-06-22 Pharmaceutical formulations
GBGB9820837.4A GB9820837D0 (en) 1998-09-24 1998-09-24 Pharmaceutical formulations
GBGB9903177.5A GB9903177D0 (en) 1999-02-13 1999-02-13 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
OA11069A true OA11069A (en) 2002-03-13

Family

ID=27269368

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900137A OA11069A (en) 1998-06-22 1999-06-18 Intranasal formulations for treating sexual disorders

Country Status (40)

Country Link
US (2) US20020040139A1 (hu)
EP (1) EP0967214B1 (hu)
JP (1) JP3263379B2 (hu)
KR (1) KR100345824B1 (hu)
AP (1) AP1178A (hu)
AR (1) AR016993A1 (hu)
AT (1) ATE269866T1 (hu)
AU (1) AU746865B2 (hu)
BG (1) BG64372B1 (hu)
BR (1) BR9903273A (hu)
CA (1) CA2275554C (hu)
CZ (1) CZ294856B6 (hu)
DE (1) DE69918222T2 (hu)
DK (1) DK0967214T3 (hu)
DZ (1) DZ2826A1 (hu)
EA (1) EA001903B1 (hu)
ES (1) ES2221733T3 (hu)
GT (1) GT199900095A (hu)
HN (1) HN1999000096A (hu)
HR (1) HRP990195B1 (hu)
HU (1) HUP9902076A3 (hu)
ID (1) ID23554A (hu)
IL (1) IL130539A0 (hu)
IS (1) IS5085A (hu)
MA (1) MA25089A1 (hu)
MY (1) MY117967A (hu)
NO (1) NO317365B1 (hu)
NZ (1) NZ336382A (hu)
OA (1) OA11069A (hu)
PA (1) PA8476301A1 (hu)
PE (1) PE20000702A1 (hu)
PT (1) PT967214E (hu)
SG (1) SG77246A1 (hu)
SI (1) SI0967214T1 (hu)
SK (1) SK284574B6 (hu)
TN (1) TNSN99129A1 (hu)
TR (1) TR199901444A2 (hu)
TW (1) TWI223598B (hu)
UA (1) UA59385C2 (hu)
YU (1) YU29699A (hu)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
CA2391968A1 (en) * 1999-11-18 2001-05-25 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
KR20010016165A (ko) * 2000-11-16 2001-03-05 정순학 성기능 장애 치료를 위한 피부에 적용하는 제제
DE10118305A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Zusammensetzungen zur nasalen Applikation
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
AU2002310086B2 (en) * 2001-05-24 2008-09-04 Alexza Pharmaceuticals, Inc. Delivery of erectile dysfunction drugs through an inhalation route
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
DE10248601B4 (de) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US7138107B2 (en) * 2003-02-18 2006-11-21 Compellis Pharmaceuticals Inhibition of olfactory neurosensory function to treat eating disorders and obesity
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
EP1607117A4 (en) 2003-03-27 2007-10-24 Bioactis Ltd APPLICATOR FOR POWDER MEDICATION IN THE NOSE CAVE
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
US20040234914A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Percussively ignited or electrically ingnited self-contained heating unit and drug-supply unit employing same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US8673360B2 (en) * 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
DK1802277T3 (da) 2004-10-18 2010-05-17 Polymun Scient Immunbio Forsch Liposomal sammensætning indeholdende en aktiv bestanddel til relaksation af glat muskulatur og terapeutisk anvendelse af sammensætningen
JP2008532973A (ja) * 2005-03-09 2008-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とｐｄｅ５−阻害剤に基づく新規な医薬組成物
ES2433661T3 (es) 2005-04-19 2013-12-12 Takeda Gmbh Roflumilast para el tratamiento de hipertensión pulmonar
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
ATE398451T1 (de) * 2005-08-29 2008-07-15 Teva Pharma Festes, teilchenförmiges tadalafil mit bimodaler teilchengrössenverteilung
GB0526283D0 (en) * 2005-12-23 2006-02-01 Givaudan Sa Compositions
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
JP5415769B2 (ja) 2006-12-26 2014-02-12 株式会社新日本科学 経鼻投与用製剤
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
DE102008004893A1 (de) 2008-01-17 2009-07-23 Add Technologies Ltd. Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung
US20110033506A1 (en) * 2008-02-08 2011-02-10 Adel Penhasi Combination dosage form of low-dose modafinil and low-dose sildenafil
DK2271347T3 (en) 2008-03-28 2016-08-15 Hale Biopharma Ventures Llc Administration of benzodiazepine compositions
MX2010013118A (es) 2008-06-04 2011-03-29 Colgate Palmolive Co Implemento de cuidado oral con sistema de cavitacion.
WO2009152344A2 (en) * 2008-06-11 2009-12-17 Comgenrx, Inc. Combination therapy using phosphodiesterase inhibitors
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
JP2011001317A (ja) * 2009-06-19 2011-01-06 Fumakilla Ltd 鼻用洗浄剤
GB2472327B (en) * 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
KR101479388B1 (ko) 2010-05-10 2015-01-05 유로-셀티큐 에스.에이. 활성제 로딩된 과립과 추가의 활성제와의 조합물
MX340188B (es) 2010-05-10 2016-06-30 Euro-Celtique S A * Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
DK3415139T3 (da) 2011-06-14 2022-06-20 Neurelis Inc Administration af benzodiazepin
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
WO2014055801A1 (en) * 2012-10-05 2014-04-10 Henkin Robert I Phosphodiesterase inhibitors for treating taste and smell disorders
CA2795324C (en) * 2012-11-09 2015-07-14 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
RU2536425C2 (ru) * 2013-01-17 2014-12-20 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция, содержащая силденафил цитрат, и способ ее приготовления
ES2744542T3 (es) * 2013-03-15 2020-02-25 Robert I Henkin Inhibidores de fosfodiesterasa para tratar trastornos gustativos y olfativos
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CN106233141B (zh) 2014-02-18 2018-08-21 罗伯特·I·汉金 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物
NO2723977T3 (hu) 2014-03-19 2018-03-10
US20170035764A1 (en) * 2015-08-03 2017-02-09 Synergistic Therapeutics, Llc Sexual dysfunction therapeutic gel
MX2019004894A (es) * 2016-10-31 2019-06-20 Suda Ltd Administración de agente activo de la mucosa.
WO2018158234A1 (en) 2017-03-02 2018-09-07 Dutch Renewable Energy B.V. Intranasal administration of physiologically active substances
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
BR112020012986A2 (pt) * 2017-12-26 2020-12-01 Ftf Pharma Private Limited formulações orais líquidas para inibidores de pde v
EP3781191A4 (en) * 2018-04-16 2022-01-19 Barista Mist Pty Ltd CAFFEINE COMPOSITIONS AND METHODS OF USE
SE542968C2 (en) * 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
EA202091615A1 (ru) 2018-12-21 2021-03-05 Аегис Терапьютикс, Ллс Интраназальные составы на основе эпинефрина и способы лечения заболевания
CA3187753A1 (en) * 2020-07-29 2022-02-03 Lido Ventures Llc Apparatus, system, and method for facilitating intranasal treatment of a patient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
SI0776895T1 (en) * 1995-11-20 1999-04-30 Eli Lilly And Company Protein kinase C inhibitor
BR9809508A (pt) * 1997-05-29 2000-06-20 Mochida Pharm Co Ltd Agente terapêutico para disfunção de ereção
WO1999027905A1 (en) * 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
TWI223598B (en) 2004-11-11
IL130539A0 (en) 2000-06-01
DZ2826A1 (fr) 2003-12-01
EP0967214A1 (en) 1999-12-29
NO317365B1 (no) 2004-10-18
AU3579499A (en) 2000-01-06
AU746865B2 (en) 2002-05-02
CZ9902257A3 (cs) 2000-11-15
KR100345824B1 (ko) 2002-07-24
PT967214E (pt) 2004-08-31
BR9903273A (pt) 2000-05-09
SG77246A1 (en) 2000-12-19
DK0967214T3 (da) 2004-09-27
CZ294856B6 (cs) 2005-03-16
ATE269866T1 (de) 2004-07-15
AP9901585A0 (en) 1999-06-30
DE69918222D1 (de) 2004-07-29
MY117967A (en) 2004-08-30
EA199900487A3 (ru) 2000-04-24
PA8476301A1 (es) 2000-09-29
ES2221733T3 (es) 2005-01-01
EP0967214B1 (en) 2004-06-23
CA2275554A1 (en) 1999-12-22
US20020040139A1 (en) 2002-04-04
IS5085A (is) 1999-12-23
PE20000702A1 (es) 2000-08-16
TNSN99129A1 (fr) 2005-11-10
AR016993A1 (es) 2001-08-01
TR199901444A2 (xx) 2000-01-21
HU9902076D0 (en) 1999-08-30
YU29699A (sh) 2003-02-28
EA001903B1 (ru) 2001-10-22
GT199900095A (es) 2000-12-13
BG64372B1 (bg) 2004-12-30
BG103510A (en) 2000-01-31
JP3263379B2 (ja) 2002-03-04
HRP990195B1 (en) 2003-04-30
JP2000034232A (ja) 2000-02-02
NO993051L (no) 1999-12-23
US20030158206A1 (en) 2003-08-21
NZ336382A (en) 1999-11-29
SI0967214T1 (en) 2004-10-31
SK81999A3 (en) 2001-01-18
HRP990195A2 (en) 2000-02-29
AP1178A (en) 2003-06-30
DE69918222T2 (de) 2005-07-28
SK284574B6 (sk) 2005-06-02
ID23554A (id) 2000-05-04
HN1999000096A (es) 2000-12-03
HUP9902076A2 (hu) 2000-05-28
UA59385C2 (uk) 2003-09-15
CA2275554C (en) 2003-06-03
EA199900487A2 (ru) 1999-12-29
HUP9902076A3 (en) 2002-03-28
NO993051D0 (no) 1999-06-21
KR20000006310A (ko) 2000-01-25
MA25089A1 (fr) 2000-12-31

Similar Documents

Publication Publication Date Title
OA11069A (en) Intranasal formulations for treating sexual disorders
EP0490689B1 (en) 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide sulphate (2:1)
WO2003039546A1 (en) New uses for anti-malarial therapeutic agents
AU2002363443A1 (en) New uses for anti-malarial therapeutic agents
US6740306B2 (en) Imidazotriazinone-containing compositions for nasal administration
EP0357550B1 (en) New use of 5-heteroaryl- or 5-aryl-substituted imidazo [2,1-a] isoquinolines
EP1137398B1 (en) Pharmaceutical preparation for inhalation of an opioid
EP1237538A2 (en) An improved pharmaceutical composition for treating male erectile dysfunction
JPH0524890B2 (hu)
JP2007512223A (ja) デヒドロエピアンドロステロンまたは硫酸デヒドロエピアンドロステロンとｐｄｅ−４阻害剤を組み合わせた喘息または慢性閉塞性肺疾患の治療
US3743733A (en) Method of treating bronchial asthma
US20040142944A1 (en) Compositions for nasal application
CN1240134A (zh) 治疗性障碍的鼻内给药制剂
MXPA99005859A (es) Formulaciones intranasales para tratar trastornos sexuales